27.09.2012 • News

Neurosearch to Sell Huntexil Drug to Israel's Teva

Danish biopharma company Neurosearch said on Thursday it had signed a 149 million Danish crowns ($25.7 million) deal with Israel's Teva Pharmaceutical Industries for the sale of its Huntington's drug Huntexil.

Under the deal, Neurosearch could also receive potential milestone payments with a total value of up to 55 million crowns, it said in a statement.

The agreement was conditional on Neurosearch shareholder approval as well as a number of standard conditions, it said.

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Top-Feature

most read